These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29137448)

  • 1. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.
    Wang J; Seebacher N; Shi H; Kan Q; Duan Z
    Oncotarget; 2017 Oct; 8(48):84559-84571. PubMed ID: 29137448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.
    Ren F; Shen J; Shi H; Hornicek FJ; Kan Q; Duan Z
    Biochim Biophys Acta; 2016 Dec; 1866(2):266-275. PubMed ID: 27717733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
    Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z
    J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer.
    Ganguly A; Chakraborty P; Banerjee K; Choudhuri SK
    Eur J Pharm Sci; 2014 Jan; 51():96-109. PubMed ID: 24044945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic approaches to reversing multidrug resistance.
    Sikic BI
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multidrug resistance (MDR) in oncology].
    Souvirón Rodríguez A; Ruiz Gómez MJ; Morales Moreno JA; Martínez Morillo M
    An Med Interna; 1997 Mar; 14(3):145-53. PubMed ID: 9235086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.
    Karai E; Szebényi K; Windt T; Fehér S; Szendi E; Dékay V; Vajdovich P; Szakács G; Füredi A
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
    Nooter K; Stoter G
    Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
    Elamanchili P; McEachern C; Burt H
    J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
    Coley HM
    Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
    Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
    Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209].
    Naito M; Nakanishi O; Tsuruo T
    Nihon Rinsho; 1997 May; 55(5):1122-7. PubMed ID: 9155163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY.
    Angelini A; Ciofani G; Conti P
    J Biol Regul Homeost Agents; 2015; 29(2):357-65. PubMed ID: 26122223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.
    Dong Y; Shao S; Hu J; Yang P
    Oral Oncol; 2009 Nov; 45(11):991-7. PubMed ID: 19631573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope.
    Haus-Cohen M; Assaraf YG; Binyamin L; Benhar I; Reiter Y
    Int J Cancer; 2004 May; 109(5):750-8. PubMed ID: 14999785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein.
    Wu F; Shao ZY; Zhai BJ; Zhao CL; Shen DM
    Ultrasound Med Biol; 2011 Jan; 37(1):151-9. PubMed ID: 21084157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.